Vera Therapeutics, Inc. (NASDAQ:VERA) Stock Holdings Lifted by SG Americas Securities LLC

SG Americas Securities LLC lifted its holdings in Vera Therapeutics, Inc. (NASDAQ:VERA) by 117.5% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 9,354 shares of the company’s stock after buying an additional 5,053 shares during the quarter. SG Americas Securities LLC’s holdings in Vera Therapeutics were worth $413,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. Public Employees Retirement Association of Colorado bought a new position in shares of Vera Therapeutics in the 2nd quarter worth about $135,000. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Vera Therapeutics in the 2nd quarter worth about $163,000. Ameritas Investment Partners Inc. lifted its position in shares of Vera Therapeutics by 20.8% in the 1st quarter. Ameritas Investment Partners Inc. now owns 4,000 shares of the company’s stock worth $172,000 after buying an additional 688 shares during the last quarter. Cetera Advisors LLC bought a new position in shares of Vera Therapeutics in the 1st quarter worth about $235,000. Finally, Quarry LP bought a new position in shares of Vera Therapeutics in the 2nd quarter worth about $235,000. 99.21% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts recently weighed in on VERA shares. Scotiabank started coverage on shares of Vera Therapeutics in a research report on Wednesday. They issued a “sector outperform” rating and a $60.00 price objective on the stock. JPMorgan Chase & Co. lifted their price objective on shares of Vera Therapeutics from $62.00 to $72.00 and gave the company an “overweight” rating in a research report on Tuesday, September 3rd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $107.00 price objective on shares of Vera Therapeutics in a research report on Tuesday, October 1st. Finally, Evercore ISI upgraded shares of Vera Therapeutics to a “strong-buy” rating in a research report on Monday, September 16th. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, Vera Therapeutics has a consensus rating of “Buy” and a consensus price target of $52.67.

Vera Therapeutics Stock Down 0.3 %

Vera Therapeutics stock opened at $39.89 on Friday. The stock has a market cap of $2.19 billion, a price-to-earnings ratio of -18.05 and a beta of 1.00. The company has a current ratio of 21.43, a quick ratio of 21.43 and a debt-to-equity ratio of 0.15. The company’s 50-day moving average price is $39.76 and its two-hundred day moving average price is $38.90. Vera Therapeutics, Inc. has a 52 week low of $9.24 and a 52 week high of $50.78.

Vera Therapeutics (NASDAQ:VERA) last released its earnings results on Thursday, August 8th. The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.06). On average, analysts expect that Vera Therapeutics, Inc. will post -2.57 EPS for the current fiscal year.

Insider Buying and Selling at Vera Therapeutics

In other news, CEO Marshall Fordyce sold 23,125 shares of Vera Therapeutics stock in a transaction that occurred on Wednesday, September 25th. The shares were sold at an average price of $46.05, for a total value of $1,064,906.25. Following the transaction, the chief executive officer now owns 307,972 shares of the company’s stock, valued at $14,182,110.60. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In other news, CEO Marshall Fordyce sold 23,125 shares of Vera Therapeutics stock in a transaction that occurred on Wednesday, September 25th. The shares were sold at an average price of $46.05, for a total value of $1,064,906.25. Following the transaction, the chief executive officer now owns 307,972 shares of the company’s stock, valued at $14,182,110.60. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Beth C. Seidenberg sold 1,177 shares of Vera Therapeutics stock in a transaction that occurred on Wednesday, September 18th. The stock was sold at an average price of $42.01, for a total transaction of $49,445.77. Following the completion of the transaction, the director now directly owns 160,376 shares in the company, valued at $6,737,395.76. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 70,023 shares of company stock valued at $2,873,156. Company insiders own 21.70% of the company’s stock.

Vera Therapeutics Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.